Skip to content

Article

Health Technology Company Fullscript Collects First-Round Bids; Centerview Advising

Share on X (opens in a new window) Share on Facebook (opens in a new window) Share on LinkedIn (opens in a new window)
✨ Summary by AI at Octus
Healthcare technology firm Fullscript is undergoing a sale process with Centerview Partners advising the company and its shareholders. The Ontario-based company, which generates EBITDA in the range of $200 million to $250 million, received first-round bids from potential buyers in July. Fullscript, founded in 2011, connects providers and patients through a platform offering supplements, laboratory testing, and clinical resources, serving over 125,000 healthcare providers and 5 million patients annually. HGGC and Snapdragon Capital Partners, which invested $240 million in Fullscript in 2021, made additional investments in May 2025, with Leonard Green & Partners as the sole lead investor.

Reporting: Paola Aurisicchio, Benjamin Taubman, Aaron Weitzman

Healthcare technology firm Fullscript is running a sale process with investment bank Centerview Partners advising the company and its shareholders, according to sources.

The Ontario, Canada-based company generates EBITDA roughly in the $200 million to $250 million range, sources said.

Fullscript received first-round bids from prospective buyers in the latter part of July, sources said.

Middle-market private equity firm HGGC and investment firm Snapdragon Capital Partners invested $240 million in Fullscript in 2021, according to an announcement at the time.

In May 2025, HGGC and Snapdragon made additional investments in Fullscript and raised a continuation vehicle for the company, with Leonard Green & Partners serving as sole lead investor.

Founded in 2011, Fullscript connects providers and patients through an integrated platform offering supplements, laboratory testing, adherence tools and clinical resources. The company serves more than 125,000 healthcare providers and more than 5 million patients annually across North America, according to its website.

Fullscript has completed acquisitions including laboratory test management platform Rupa Health in 2024 and integrative healthcare company Emerson Ecologics in 2022.

Elsewhere in the healthcare sector, Octus reported last month that Warburg Pincus and Great Hill Partners-backed employee healthcare benefits manager ParetoHealth was preparing to explore a sale, with JPMorgan serving as its advisor. The company has EBITDA in the $250 million to $275 million range.

Financing details for similar companies to Fullscript can be found on Octus’ Private Credit Dashboard.

WhiteHorse Capital, the direct lending unit of H.I.G. Capital, provided financing as part of a first lien credit facility to support Gryphon Investors’ 2021 acquisition of nutritional supplement company Metagenics from Alticor, according to a press release.

Newly issued senior direct lending facilities to back M&A in the healthcare sector widened to an average of SOFR+510 bps in the second quarter of 2026 from SOFR+492 bps in the first quarter of 2026, according to Octus’ Private Credit Dashboard.

Fullscript, HGGC, Snapdragon, Leonard Green and Centerview did not return requests for comment.

This publication has been prepared by Octus Intelligence, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2026 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.